Bicara Therapeutics Common Stock Net Income

Bicara Therapeutics Common Stock (BCAX) currently reports a net income of $-190M as of June 2026. That compares with $-100M in the prior-year period — down 80.5% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Bicara Therapeutics Common Stock's net income history and peer comparisons.

Bicara Therapeutics Common Stock's net income decreased from $-100M to $-190M — a 80.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bicara Therapeutics Common Stock's net income of $-190M is lower than the Healthcare sector average of $16B. That is roughly 101.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Bicara Therapeutics Common Stock reported $-190M in net income as of June 2026. That compares with $-100M in the prior-year period — down 80.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-190M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Bicara Therapeutics Common Stock, and consider following BCAX for alerts when major investors trade the stock.